We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
St. Soldier Institute of Pharmacy, Lidhran Campus Behind NIT ( R.E.C) Jalandhar- Amritsar byepass, NH-1, Jalandhar, Punjab, India 144011
Diabetic Kidney disease or DKD is a common condition that worldwide affects a large number of Diabetics. Diabetic kidney disease arises when diabetes-related blood sugar level raises and simultaneously harms the Kidneys. Harmful consequences leads to change in blood flow and pressure inside the kidneys and cause inflammation throughout the body due to excessive Sugar and fat metabolism in blood. An obstacle faced during the accurate diagnoses of DKD is that it shows the same symptoms as other kidney disorders. So in order to accurately diagnose DKD, Physician requires newly improved testing that can monitor its progression, determine whether therapies are effective and predict potential future outcomes. Initial cause is blood sugar level, which cause the body to generate an excessive amount of harmful molecules when blood sugar level is high and function inside cells and tissues like a wrecking ball. Most of the people are unaware of its potential danger. It causes and a large of people are particularly unaware of even suffering from DKD, despite the fact that it is a major health concern. Another significant issue of DKD is its High expense treatment which is a major concern for patients, their families, healthcare systemandeconomies. In the early stages most people feel completely normal until the kidney damage is extremely severe there are typically no noticeable symptoms and by then major consequences have frequently begun. Another important worry is the lack of good statistics on the incidence of diabetic kidney disease in many places, as well as the absence of systematic screening for kidney abnormalities in diabetes patients, which frequently leads to the disease being found too late. Doctors could delay or stop the damage to help individuals. It's early diagnose will help the patient live a more longer and healthier lives as well as reducing the financial burden and emotional impact on patients and their families. Early diagnose will help physicians to provide a more appropriate medication and environment condition in which they can recover faster. But unfortunately DKD is often identified when kidney are for beyond damage and close to failure.
Diabetic kidney disease is a kidney condition that is caused by diabetes which is going to be discussed in this article. A major factor which aggravate this illness is inflammation or swelling and irritation within the kidney [1]. Early detection of bodily inflammatory markers are crucial. We can prevent the issue from worsening only by promptly identifying the warning indicators or symptoms before it causes any significant harm [2].
The Diabetic kidney disease is also known as diabetic nephropathy. It is a unique kind of kidney disease that only affects individuals with diabetes who also experience chronic kidney damage [3]. changing how the kidneys work as well as how the body eliminates waste and fluids. Albuminuria, edema, polyuria, nausea, anemia, and hypertension are the signs of this illness [4].
For those peoples who already have diabetes, this kidney issue raises their risk of dying by about 31%. The risk increases with the severity of kidney disease [5]. Early detection of diabetic kidney disease (DKD) is crucial since it not only saves a significant amount of money for families and the nation as a whole, but it also lessens the considerable harm that DKD does to people's health. Early detection allows medical professionals to begin therapies that slow down kidney deterioration and avoid more serious issues down the road. DKD is frequently concealed and initially undetectable; most people experience no symptoms at all for a considerable amount of time.
Early detection of diabetic kidney disease, or DKD, is a wise and economical strategy to lessen the total damage and consequences of the condition.This study examines the prevalence of DKD worldwide, the primary risk factors that raise the likelihood of developing it, and potential early warning indicators that manifest before the condition worsens [6].
Epidemiology and Perspectives in DKD
At a global level, diabetes is a relatively concerning health issue. At present at least 10.5% of people are suffering from diabetes, mostly aged between 20 years to 75 years. According to experts by 2030 this figure will significantly increase and cross over 643 million [7]. Diabetes usually goes undiagnosed for the first four to seven years and by the time physician diagnose it a significant damage has already been done to the body which remains undetected as its symptoms doesn't manifest until much later [8]
This illness worsens over time due to a number of internal factors, including persistent inflammation, irregularities in the body's handling of chemicals and energy (metabolic disorders), and problems with blood flow and pressure (hemodynamic issues). Since focusing on and managing the inflammatory process appears to be one of the most promising approaches to create novel treatments and halt the progression of the disease, scientists and medical professionals have been paying much more attention to this aspect lately [9].
Diabetic kidney disease, affects around 38.8% of people with diabetes in China.However, only about 2.9% of the overall population—including those with diabetes—has this illness in rural areas [10].DKD affected 34.4% of Indians and 62.3% of participants in a multicenter trial [11]. Diabetes and chronic renal disease are most prevalent among older adults in the Eastern Mediterranean region. About 15.3% of type 2 diabetes patients in Japan have a low estimated glomerular filtration rate (eGFR), which indicates that their kidneys are damaged or functioning less well [12]. Approximately 28% of individuals with type 2 diabetes in the UK experienced renal issues after being followed for approximately 15 years, according to a significant long-term study. Diabetic kidney disease, or kidney impairment brought on by diabetes, affects around 2.2% of the US population overall. As more individuals get diabetes, this percentage has been rising [13].The study highlights how critical it is to increase the public awareness for diabetic kidney disease and increase efforts to prevent it.
Diabetic kidney disease is a highly common and dangerous problem in the world. Approximately 1.75 out of every 100 patients with diabetes (or roughly 1.75%) acquire this illness, which causes kidney damage over time [14]. Different rates of DKD have been found in China, India, and the United Arab Emirates, according to research.
Pathophysiology of DKD
Inflammatory, haemodynamic, and metabolic factors interact in a complex way to cause diabetic kidney disease [15]. Endothelial dysfunction, oxidative stress, tubule and glomerulus damage, and other metabolic responses are triggered by hyperglycemia [16]. While renal hyperfiltration and increased intraglomerular pressure cause glomerular injury, tubular dysfunction impacts the reabsorption and secretion processes [17]. Chronic inflammation and fibrosis exacerbate renal damage and cause a gradual decline in kidney function [12]. In order to preserve the renal function and improve diabetic kidney disease outcomes, as it is intended by developing therapies which require a considerable amount of understanding about these pathophysiological processes.
Figure 1: 1,2 The Pathophysiology of Diabetic Kidney
A detailed information regarding the various factors that lead to the beginning and progression of diabetic kidney disease, further highlighting the concerning issue and need for the comprehensive care techniques.
Polyol, hexosamine, advanced glycation end products and protein kinase C are made to use in metabolic pathways [19]. Kidney damage is caused by hyperglycemia which produces glycosylated end products, synthesising diacylglycerol and activating protein C [20].
Limitations of Conventional Biomarkers
Diagnostic indicators of diabetic kidney disease are albuminuria and a significant decline in estimated glomerular filtration rate (eGRF) as it is measured by blood creatinine levels [21]. To predict future progression and assess treatment success is done by using albuminuria as a valid biomarker. An important tool in diagnosing and treating diabetic kidney is urinary albumin excretion (UAE), that stratifies and to assess the severity of albuminuria [22].
A key clinical biomarker that is used to assess the prognosis of diabetic kidney disease is glomerular filtration rate (GFR). There is a clear link between structural damage and kidney function, even though this relationship is less obvious with modest albuminuria or a little change or decrease in glomerular filtration rate [23].
Changes in current and earlier estimated GFRs (eGFRs) are crucial markers of how the condition is expected to progress. The CKD-EPI and MDRD equations are frequently used to estimate glomerular filtration rates (GFR) [24]. It is crucial to note, however, that these formulae may underestimate or overestimate the actual GFR. This mismatch could be due to compensatory changes in the functioning of the remaining nephrons [25]. The diagnostic and follow-up approaches that are now in use have limitations, especially for people with the common normoalbuminuric phenotype who lack specific therapeutic alternatives [26].
The study emphasises the need for innovative biomarkers to improve diagnostic and monitoring procedures for diabetic kidney disease, with a focus on their efficacy in diagnosing, tracking progression, assessing therapy response, and predicting prognosis [27]. The study will look into the practical application of novel biomarkers as shown in Figure 2.
Figure 2: 1, 2. This table presents a complete overview of conventional biomarkers [28], [29] versus innovative biomarkers [30], [31], [32] that are routinely used in clinical practice to diagnose, monitor, and manage diabetic kidney disease, with an emphasis on kidney function, damage, and overall metabolic management.
Novel Biomarkers in Diabetic Kidney Disease
In diabetes related disease, early detection is crucial but traditional diagnostic procedures led to frequent delay in diagnosis [33]. The study of DKD pathophysiology and causes has highlighted the necessity of developing new biomarkers in urine and serum using proteomics and metabolomics.
Biomarkers have been created that can help in the diagnosis of diabetic kidney disease, leading to further advancement. Serum creatinine, opposed to the traditional ones, can improve the accuracy of DKD examinations, which makes them more of a precise and accurate instrument for monitoring the functions of the kidney [34].
The AKI agreement emphasises that biomarkers should serve as an extra test to identify the individuals who can benefit from the cardiovascular risk prevention and treatment techniques rather than replace it with the traditional testing and clinical evaluations altogether [35].
Figure 3: 1,2 Potential Risk factors of DKD [36], [37]
Biomarkers for the early diagnosis of DKD
To identify renal impairment prior to the onset of clinical signs, biomarkers are being used such as urine albumin excretion rate, UAER, UACR and eGFR in the diagnosis of diabetic kidney disease [6]. L-FABP, NGAL, and KIM-1 are examples of novel biomarkers that may be used to detect kidney damage early. To slow down the development of diabetic kidney disease and its consequences, early treatment and special tailored approaches are being employed including various indicators into clinical practice.
To properly treat kidney disease, timely diagnosis and appropriate medication are critical. They can significantly reduce or slow down the progression of the illness as well as increase life expectancy and lessen the stress both mentally and physically, further relieving their financial stress [38]. Albuminuria and serum creatinine serve as biomarkers but their absence can hinder the timely diagnosis of a condition [39]. Although some research shows that albuminuria is an insensitive biomarker and unreliable even serum creatinine is not considered such a strong predictor [40]. As a result, new biomarkers with higher sensitivity and predictability are required for early diagnosis and treatment of DKD, as present biomarkers are insufficiently sensitive.
Figure 4: 1,2 Potential Biomarkers for the early diagnosis of DKD [41], [42], [43]
Diagnosis of DKD
Figure 5: Type of biomarker are more important for disease diagnosis and treatment
Diabetic kidney disease is diagnosed by evaluating urine albumin excretion and glomerular filtration rate (GFR) [44]. While GFR monitoring and chronic albuminuria help to stage the seriousness of diabetic kidney disease, the early renal impairment is identified by albuminuria screening [45]. Further diagnostic techniques include kidney biopsies, serum Biomarkers and renal imaging. Early detection and surveillance are essential for the prompt intervention and therapy to prevent diabetic kidney disease from further processing to end-stage renal disease.
Diabetic kidney disease is diagnosed using a variety of diagnostic procedures that aid in the early discovery, in monitoring illness progress and directing decisions for the treatment. These diagnostic procedures specially emphasize the indicator of kidney damage, function and generally metabolic control.
Various diagnostic assessments used in the diagnosis of DKD
B. Diagnostic Confirmation
C. Additional Tests
D. Evaluation of Complications
E. Monitoring and Follow-up
UACR measurements and GFR assessments should be less than 60ml/min per 1.73m2 when diagnosed. It is within acceptable limits, even if GFR declines in situations of tyoe 1 and type 2 diabetes. Diabetics must check their creatinine levels annually. The MDRD formula or the CKD-EPI equation are being used to compute GFR. The screening for nephropathy in all patients with type 2 diabetes for at least five years has been recommended by the American Diabetes Association.
A tabular representation of the management and therapy of diabetic kidney disease (DKD).
For example:- Atorvastatin, Rosuvastatin
For example:- Enalapril, Irbesartan.
For example:- Dietary counseling
For example:- Dietary counseling
For example:- Aspirin, Clopidogrel
For example:- Enoxaparin, Apixaban
For example:- Blood pressure, UACR
For example:-Nephrologist appointment
CONCLUSION
As a result of continuous research into possible targets for prediction, monitoring and prevention. In recent years new and novel treatment has arisen in DKD. Nonetheless new developments are being incorporated into clinical practices through various makers. In future, to enhance doctors options for more effective and personalised therapies. Advances are being made in the creation of novel chemicals and therapeutic techniques. DKD is a medical calamity that has a high occuran roles, in addition there's a scarcity of new signs for early diagnosis and even the existing detection tools are proven ineffective. To assess the potential and applicability of novel plasma and urine biomarkers is required to have multinational and multicenter epidemiological studies. In recent years new treatments for diabetic kidney disease have progressed as a result of continuous search into various possible targets for monitoring prediction and prevention of DKD. These incorporation of markers into clinical practices has made advances in the creation of more effective treatments and new therapeutic techniques are promised to enhance doctors choices in the identification and possible treatments in diabetic kidney disease.
REFERENCES
Yuvraj Rattu, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Gaurav Hastir, Review on Diabetic Kidney Disease, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 9, 1229-1241. https://doi.org/10.5281/zenodo.22704747
10.5281/zenodo.22704747